FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128426105> ?p ?o ?g. }

• W2128426105 endingPage "6" @default.
• W2128426105 startingPage "854" @default.
• W2128426105 abstract "CYCLOSPORIN A (CsA) (Atopica, Atoplus soft capsules; Novartis Animal Health) was introduced recently as an oral microemulsion formulation for the treatment of dogs with atopic dermatitis. Several randomised, controlled and open clinical studies have proven its clinical efficacy (Olivry and others 2002, Steffan and others 2003, 2004). Based on pharmacokinetic data, administration of CsA is recommended two hours before or after feeding, as its bioavailability decreases and the variability of individual blood concentrations increases when the drug is given with food (Steffan and others 2004). Dosing fasted dogs is therefore recommended to optimise the drug’s bioavailability. However, the clinical response of dogs after dosing with or without food has never been evaluated. This short communication describes a study to determine whether the administration of CsA with or without food could influence the clinical response in dogs with atopic dermatitis. Twenty-five dogs with non-seasonal atopic dermatitis, diagnosed by Prelaud’s criteria (Prelaud and others 1998) and by exclusion of differential diagnoses, were included in a multicentre, randomised study involving seven investigators in Germany. All the dogs received approximately 5 mg/kg/day CsA. The animals were randomly and sequentially divided into two groups by the lead investigator, independent of the study centre, alternating between group 1 and 2. As the various centres included dogs at different time points, the number of dogs in each group was not identical at each centre. The 15 dogs in group 1 received CsA with a meal, while the 10 dogs in group 2 were given the drug at least two hours before or after feeding. Dogs were evaluated before treatment and monthly for six months thereafter. A dose tapering regimen was applied, as described by Steffan and others (2003). The canine atopic dermatitis extent and severity index (CADESI), with scores of 0 to 3 for erythema, lichenification and ex coriation at 40 different body sites, was used by the clinician at each centre, as previously described by Olivry and others (2002); pruritus was evaluated by the owner, using a visual analogue scale from 0 to 100. If the CADESI score increased above baseline, the dog was excluded from the study. If the CADESI score at any given visit was reduced by more than 50 per cent and the pruritus was adequately controlled, administration of CsA was reduced to every second day of treatment. If the CADESI score had improved by more than 75 per cent from baseline and pruritus was well controlled, the drug was administered twice weekly. If, on subsequent visits, the CADESI scores or pruritus increased, the frequency of administration was increased again to the previous level. During a selection period of four weeks, all the dogs were treated with a long-lasting flea adulticide spot-on formulation such as selamectin, imidacloprid, fipronil or permethrin. Fipronil was used monthly during the study. Systemic antibiotics and antifungal drugs were administered as required for the treatment of secondary infections. Antipruritic drugs had to be withdrawn before inclusion in the study (CsA for eight weeks, injectable glucocorticoids for four weeks, oral/ topical glucocorticoids for one week and allergen-specific immunotherapy for two weeks). Fatty acid supplementation Veterinary Record (2006) 159, 854-856" @default.
• W2128426105 created "2016-06-24" @default.
• W2128426105 creator A5018810219 @default.
• W2128426105 creator A5030990256 @default.
• W2128426105 creator A5044229159 @default.
• W2128426105 creator A5053333212 @default.
• W2128426105 creator A5061856115 @default.
• W2128426105 creator A5070076227 @default.
• W2128426105 date "2006-12-16" @default.
• W2128426105 modified "2023-09-23" @default.
• W2128426105 title "Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis." @default.
• W2128426105 cites W1971037886 @default.
• W2128426105 cites W2019418296 @default.
• W2128426105 cites W2038401270 @default.
• W2128426105 cites W2155444004 @default.
• W2128426105 cites W2297267958 @default.
• W2128426105 cites W2398505315 @default.
• W2128426105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17172483" @default.
• W2128426105 hasPublicationYear "2006" @default.
• W2128426105 type Work @default.
• W2128426105 sameAs 2128426105 @default.
• W2128426105 citedByCount "7" @default.
• W2128426105 countsByYear W21284261052014 @default.
• W2128426105 countsByYear W21284261052015 @default.
• W2128426105 countsByYear W21284261052018 @default.
• W2128426105 countsByYear W21284261052022 @default.
• W2128426105 crossrefType "journal-article" @default.
• W2128426105 hasAuthorship W2128426105A5018810219 @default.
• W2128426105 hasAuthorship W2128426105A5030990256 @default.
• W2128426105 hasAuthorship W2128426105A5044229159 @default.
• W2128426105 hasAuthorship W2128426105A5053333212 @default.
• W2128426105 hasAuthorship W2128426105A5061856115 @default.
• W2128426105 hasAuthorship W2128426105A5070076227 @default.
• W2128426105 hasConcept C112705442 @default.
• W2128426105 hasConcept C126322002 @default.
• W2128426105 hasConcept C16005928 @default.
• W2128426105 hasConcept C181389837 @default.
• W2128426105 hasConcept C2777288759 @default.
• W2128426105 hasConcept C2778329239 @default.
• W2128426105 hasConcept C2778345441 @default.
• W2128426105 hasConcept C535046627 @default.
• W2128426105 hasConcept C71924100 @default.
• W2128426105 hasConcept C98274493 @default.
• W2128426105 hasConceptScore W2128426105C112705442 @default.
• W2128426105 hasConceptScore W2128426105C126322002 @default.
• W2128426105 hasConceptScore W2128426105C16005928 @default.
• W2128426105 hasConceptScore W2128426105C181389837 @default.
• W2128426105 hasConceptScore W2128426105C2777288759 @default.
• W2128426105 hasConceptScore W2128426105C2778329239 @default.
• W2128426105 hasConceptScore W2128426105C2778345441 @default.
• W2128426105 hasConceptScore W2128426105C535046627 @default.
• W2128426105 hasConceptScore W2128426105C71924100 @default.
• W2128426105 hasConceptScore W2128426105C98274493 @default.
• W2128426105 hasIssue "25" @default.
• W2128426105 hasLocation W21284261051 @default.
• W2128426105 hasOpenAccess W2128426105 @default.
• W2128426105 hasPrimaryLocation W21284261051 @default.
• W2128426105 hasRelatedWork W1965470307 @default.
• W2128426105 hasRelatedWork W1971037886 @default.
• W2128426105 hasRelatedWork W1976115131 @default.
• W2128426105 hasRelatedWork W1983884060 @default.
• W2128426105 hasRelatedWork W2018320784 @default.
• W2128426105 hasRelatedWork W2019418296 @default.
• W2128426105 hasRelatedWork W2021799651 @default.
• W2128426105 hasRelatedWork W2028765226 @default.
• W2128426105 hasRelatedWork W2038401270 @default.
• W2128426105 hasRelatedWork W2038781769 @default.
• W2128426105 hasRelatedWork W2040838538 @default.
• W2128426105 hasRelatedWork W2055595145 @default.
• W2128426105 hasRelatedWork W2057203027 @default.
• W2128426105 hasRelatedWork W2061953334 @default.
• W2128426105 hasRelatedWork W2098852002 @default.
• W2128426105 hasRelatedWork W2106156910 @default.
• W2128426105 hasRelatedWork W2117443974 @default.
• W2128426105 hasRelatedWork W2138197074 @default.
• W2128426105 hasRelatedWork W2142684368 @default.
• W2128426105 hasRelatedWork W2155444004 @default.
• W2128426105 hasVolume "159" @default.
• W2128426105 isParatext "false" @default.
• W2128426105 isRetracted "false" @default.
• W2128426105 magId "2128426105" @default.
• W2128426105 workType "article" @default.